Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

Aim. To compare efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent Asthma.
Study population. Patients with Asthma (Stage II):47 who received Salamol (300 mcg/day) and Beclason (750-1000 mcg/day) during 6 month (Group I) and 29 who received Salamol (600- 1200 mcg/day) during 6 month (Group II). Groups were comparable on age, sex and Asthma duration .
Methods/ Spirometry, blood glucose level and test of tolerance to glucose, blood potassium and calcium were performed before and after 6 month of treatment.
Results. Increasing of FEV1 was authentically different (p<0.05) in Group I (20.6±]4.7%) in comparison with Group II (12.6±]3.1%). Baseline level of blood glucose, potassium and calcium and test of tolerance to glucose were normal in all patients. After 6-month therapy in Group I there was not significant changes in the level of blood glucose, calcium and potassium . Low tolerance to glucose was found in 2.1% of cases. In Group II authentical decreasing of potassium level was found in 6.9% of patients, decreasing of calcium level – in 3.4%; low tolerance to glucose was established in 6.9% of cases. Besides in 3.4% of patients Diabetes Mellitus was developed.
Conclusion. Long-term therapy with Salamol combined with Beclason allows to gain control on the course of Asthma and doesn't change significantly the indices of mineral and glucose metabolism. Long-term therapy with high doses of Salamol lead to the increasing of blood potassium and calcium level and cause significant changes of glucose metabolism. This therapy doesn't allow the Asthma stabilization. Thus, combination of beta-agonists and inhaled corticosteroids is more effective and save in the treatment of mild persistent Asthma.

Rating:

Share or cite this content

Citations should be made in the following way:
K. E. Bogatska, T. O. Pertzeva, K. Y. Gashynova (Dnepropetrovsk, Ukraine). Efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent asthma. Eur Respir J 2002; 20: Suppl. 38, 383

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Assessment of long-term effects of combined extra-fine beclomethasone and formoterol treatment in asthma patients using functional imaging Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004